Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 5

1.

Assessment of celecoxib pharmacodynamics in pancreatic cancer.

Jimeno A, Amador ML, Kulesza P, Wang X, Rubio-Viqueira B, Zhang X, Chan A, Wheelhouse J, Kuramochi H, Tanaka K, Danenberg K, Messersmith WA, Almuete V, Hruban RH, Maitra A, Yeo CJ, Hidalgo M.

Mol Cancer Ther. 2006 Dec;5(12):3240-7.

2.

Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs.

Schönthal AH, Chen TC, Hofman FM, Louie SG, Petasis NA.

Expert Opin Investig Drugs. 2008 Feb;17(2):197-208. doi: 10.1517/13543784.17.2.197. Review.

PMID:
18230053
3.

Celecoxib and Bcl-2: emerging possibilities for anticancer drug design.

Winfield LL, Payton-Stewart F.

Future Med Chem. 2012 Mar;4(3):361-83. doi: 10.4155/fmc.11.177. Review.

4.

Potent chemopreventive agents against pancreatic cancer.

Nishikawa A, Furukawa F, Lee IS, Tanaka T, Hirose M.

Curr Cancer Drug Targets. 2004 Jun;4(4):373-84. Review.

PMID:
15180502
5.

COX and PPAR: possible interactions in pancreatic cancer.

Eibl G, Reber HA, Hines OJ, Go VL.

Pancreas. 2004 Nov;29(4):247-53. Review. No abstract available.

PMID:
15502639

Supplemental Content

Support Center